Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy.
Anticancer Res
; 38(6): 3559-3566, 2018 Jun.
Article
in En
| MEDLINE
| ID: mdl-29848710
ABSTRACT
BACKGROUND/AIM:
The purpose of this study was to consider appropriate application of liquid and re-biopsy through analysis of current status in practice. PATIENTS ANDMETHODS:
We performed a retrospective analysis of 22 patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer who exhibited 1st/2nd generation EGFR-tyrosine kinase inhibitors resistance. The cobas® method was used to detect T790M with re-biopsy and the mutation-biased PCR and quenched probe method was used with liquid biopsy.RESULTS:
T790M detection rate was 52% with re-biopsy and 58% with liquid biopsy. The concordance between tissue and plasma was 58%. One patient who was T790M-positive with liquid biopsy showed heterogeneity among metastatic lesions in terms of osimertinib efficacy, as revealed by T790M detection with re-biopsy.CONCLUSION:
Liquid biopsy reflects the whole body, whereas re-biopsy is useful for spatial diagnosis. Considering these characteristics, a combination of liquid and re-biopsy contribute to enhanced treatment.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biomarkers, Tumor
/
Drug Resistance, Neoplasm
/
Protein Kinase Inhibitors
/
ErbB Receptors
/
Mutation
Type of study:
Diagnostic_studies
/
Observational_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Anticancer Res
Year:
2018
Document type:
Article
Affiliation country:
Japan